Summarized by Masters of Longevity from Fight Aging!.
A conservative critique assesses geroscience progress and argues many longevity approaches are heterogeneous and not equally supported by human-proven evidence.
Key Takeaways
- Repurposed drugs like metformin and rapamycin have the most extensive preclinical and translational evidence supporting potential geroprotection.
- Senolytics, NAD+ precursors, taurine, and epigenetic reprogramming remain at varied translational stages from promising animal data to early human studies.
- Major gaps persist including lack of accepted aging biomarkers, uncertain clinical endpoints, heterogeneous responses, and limited long-term safety data.
